title: [The effect of cyclophosphamide, thalidomide and dexamethasone combination therapy in relapsed/refractory multiple myeloma].
abstract: OBJECTIVE
  To investigate the effect of the combination of thalidomide, cyclophosphamide and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
  
  
  METHODS
  20 relapsed/refractory multiple myeloma patients received thalidomide (200 mg/d), cyclophosphamide (300 mg.m(-2).d(-1), d1-4, every 4 weeks) and pulsed dexamethasone (20-40 mg/d, d1-4, every 4 weeks).
  
  
  RESULTS
  After 3 cycles of therapy, 9 cases obtained partial remission (PR), 4 had minimal responses (MR), 5 were of no change and 2 had progressive disease. After 6 cycles of therapy, 13 patients achieved PR and 5 had MR.
  
  
  CONCLUSIONS
  The combination of thalidomide, cyclophosphamide and dexamethasone is a promising treatment regime for relapsed/refractory multiple myeloma.
authors.affiliation: Department of Hematology and Oncology, Affiliated Beijing Chaoyang Hospital of Capital University of Medical Sciences, Beijing 100020, China. gaowenpingping@sohu.com
authors.forename: Wen
authors.initials: W
authors.lastname: Gao
authors.forename: Na
authors.initials: N
authors.lastname: An
authors.forename: Shi-lun
authors.initials: SL
authors.lastname: Chen
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D012008:Recurrence; D013792:Thalidomide / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D013792:Thalidomide; D003907:Dexamethasone; D003520:Cyclophosphamide